ArrePath Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ArrePath's estimated annual revenue is currently $1.7M per year.(i)
  • ArrePath's estimated revenue per employee is $77,500

Employee Data

  • ArrePath has 22 Employees.(i)
  • ArrePath grew their employee count by 83% last year.

ArrePath's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
VP, MicrobiologyReveal Email/Phone
3
VP, Technology Platform and Data ScienceReveal Email/Phone
4
Data Scientist IIReveal Email/Phone
5
Lead Data Scientist, Computer VisionReveal Email/Phone
6
Executive AssistantReveal Email/Phone
7
Senior ScientistReveal Email/Phone
8
Data Scientist IIReveal Email/Phone
9
Technical Lead, Machine LearningReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.5M55-21%N/AN/A
#2
$0.2M10%N/AN/A
#3
$8.5M55-29%N/AN/A
#4
$108.5M5002%N/AN/A
#5
$0.8M50%N/AN/A
#6
$0.6M40%N/AN/A
#7
$14.7M68-23%$206.4MN/A
#8
$492.2M1503-15%$568MN/A
#9
$1.1M7-42%N/AN/A
#10
$4.5M290%N/AN/A
Add Company

What Is ArrePath?

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$1.7M

Revenue (est)

83%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.4M22-15%N/A
#2
$2.8M22-19%N/A
#3
$2.6M220%N/A
#4
$2.3M23-4%N/A
#5
$7.5M23-8%$38.7M